Q&A published 14 March 2011 [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2011-03-16 14:44 (4346 d 07:31 ago) – Posting: # 6762
Views: 32,510

Dear all,

the clarification is part of the recent version of the “Questions & Answers: Positions on specific questions addressed to the Pharmacokinetics Working Party” EMA/618604/2000 Rev. 3, dated 26 January 2011, published 14 March 2011.
The interesting part is Section 11. Clarification on the recommended statistical method for the analysis of a bioequivalence study (pages 21–32).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
22 visitors (0 registered, 22 guests [including 7 identified bots]).
Forum time: 22:16 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5